Curing Cancer with Nanotherapy Continues to be an Elusive Goal

Nanotechnology has aimed to address limitations of new drug design by “repackaging” FDA approved drugs without compromising their therapeutic benefits while suppressing undesired side effects suffered patients undergoing chemotherapy. The major hurdles faced small molecular in treating cancer include hydrophobicity, rapid hepatic and renal clearance, short circulation time, off target toxicity resistance. Most these factors are addressed using nano formulations comprising lipids or polymers simultaneously striving enhance the index chemotherapeutic drugs.